UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
European journal of gastroenterology & hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
ribavirin | ledipasvir and sofosbuvir | hepatitis C virus | ombitasvir and dasabuvir | genotype 1 | adverse events | randomized | direct-acting antivirals | paritaprevir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Fatigue - chemically induced | Drug Therapy, Combination - adverse effects | Ritonavir - adverse effects | Adult | Female | Fluorenes - adverse effects | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Headache - chemically induced | Antiviral Agents - therapeutic use | Anemia - chemically induced | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Uracil - adverse effects | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Viral Load - drug effects | Uracil - analogs & derivatives | Drugs | Antiviral agents | Complications and side effects | Treatment outcome | Usage | Analysis | Adverse and side effects | Hepatitis C | Drug therapy | Risk factors | Index Medicus
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | Biological and medical sciences | General aspects | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Middle Aged | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - adverse effects | Quinolones - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Protease Inhibitors - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Organophosphonates - adverse effects | Drug Therapy, Combination - methods | HIV | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Adults | Protease inhibitors | Proteases | Antiretroviral drugs | Patient satisfaction | Drug therapy | Laboratories | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | Biological and medical sciences | General aspects | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | RNA, Viral - isolation & purification | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Retreatment | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Ritonavir | Infections | RNA polymerase | Pruritus | Patients | Ribavirin | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Dermatitis, ISSN 1710-3568, 05/2016, Volume 27, Issue 3, pp. 110 - 118
Life Sciences & Biomedicine | Dermatology | Science & Technology | Allergens - adverse effects | Ointments - adverse effects | Asteraceae - adverse effects | Lanolin - adverse effects | Ointments - chemistry | Humans | Child, Preschool | Infant | Propylene Glycol - adverse effects | Perineum | Diapers, Infant - adverse effects | Dermatitis, Allergic Contact - etiology | alpha-Tocopherol - adverse effects | Skin Cream - chemistry | Perfume - adverse effects | Carbamates - adverse effects | Parabens - adverse effects | Skin Cream - adverse effects | Infant, Newborn | Plant Extracts - adverse effects | Index Medicus
Journal Article